on 15 Oct 2024
Last Applicant/ Owned by
Convergence Bio, Inc.
800 Boylston St, Ste 2222
Boston, MASSACHUSETTS, 02199
Serial Number
UK00004111971 filed on 15th Oct 2024
Registration Number
UK00004111971 registered on
10th Jan 2025
Correspondent Information
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place, 78 Cannon Street
London,
EC4N 6AF
Pharmaceuticals; medical preparations; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; vaccines for human use; pharmaceutical preparations, vaccines and medical therapeutics for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; nutritional and dietary supplements; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss.
Research, design and development of pharmaceuticals; Research, design and development of medical preparations; Research, design and development of medical technology; research and development of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; research and development of therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; development of pharmaceutical preparations, vaccines and medicines; medical research for development of therapeutic modalities for treatment of diseases; drug development and discovery; assays and reagents for use in scientific and biomedical research; clinical studies; preclinical and clinical development of therapeutic products; information, consultancy and advisory services in relation to all of the above.
UK00004111971
Word
Individual